Does subsidizing the private for‐profit sector benefit the poor? Evidence from national antimalarial subsidies in Nigeria and Uganda

Sarah Tougher, Kara Hanson and Catherine A. Goodman

Health Economics, 2021, vol. 30, issue 10, 2510-2530

Abstract: Subsidising quality‐assured artemisinin combination therapies (QAACTs) for distribution in the for‐profit sector is a controversial strategy for improving access. The Affordable Medicines Facility—malaria (AMFm) was the largest initiative of this kind. We assessed the equity of AMFm in two ways using nationally representative household survey data on care seeking for children from Nigeria and Uganda. First, the delivery of subsidized drugs through the for‐profit sector via AMFm was compared with two alternative mechanisms: subsidized delivery in public health facilities and unsubsidized delivery in the for‐profit sector. Second, we developed a novel extension of benefit incidence analysis (BIA) methods based on the concept of pass‐through, and applied them to Uganda. In Nigeria, the use of subsidized QAACTs from both public health facilities and for‐profit outlets was concentrated among the rich, while in Uganda, the use of QAACTs from both sources was concentrated among the poor. Similarly, the BIA of AMFm found that the intervention was pro‐poor in Uganda. Unsubsidized antimalarials from for‐profit outlets were distributed equally across wealth quintiles in both countries. Private sector subsidies may have a role in bolstering access to effective malaria treatments, including among the poor, but the equity impact of subsidies may depend on context.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.4386

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:30:y:2021:i:10:p:2510-2530

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().